China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8

China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of .8

China SXT Pharmaceuticals, Inc.

TAIZHOU, China, March 14, 2022 (World NEWSWIRE) — China SXT Prescribed drugs, Inc. (“SXTC” or the “Enterprise”), (NASDAQ: SXTC), a specialty pharmaceutical corporation concentrating on the investigation, development, producing, advertising, and income of Conventional Chinese Medicine Pieces (“TCMPs”), which includes Innovative TCMPs (Instantly-Oral TCMP and Right after-Soaking-Oral TCMP), fantastic TCMPs, standard TCMPs, and TCM Homologous Nutritional supplements (“TCMHS”), right now introduced that it entered into a securities order agreement to challenge a convertible promissory take note in the unique principal total of $2,804,848.00 to Streeterville Money, LLC, a Utah confined liability organization.

The 12-month note shall bear fascination at the level of 6% for every annum. Any time immediately after ninety (90) times of issuance, the investor could elect to transform all or any part of the take note at a mounted conversion price tag, originally $.30. Any time soon after ninety (90) days of issuance, all or any portion of the notice may well be convertible into everyday shares of SXTC at a redemption conversion price of the decrease of (i) the Financial institution Conversion Selling price which is to begin with $.30 and (ii)80% of the regular of the most affordable VWAP throughout the fifteen (15) investing times straight away previous the conversion see is delivered, matter to month to month conversion limitation of $600,000. The investor shall not provide extra than 15% of the weekly investing quantity in any specified week in the open industry so long as there is no event of default. The Corporation intends to use the internet proceeds from this featuring for standard corporate functions, including, but not restricted to, performing money and other enterprise possibilities.

The closing of the giving is envisioned to come about on or about March 16, 2022, subject matter to customary closing ailments.

This featuring is being produced pursuant to an productive shelf registration statement on Form F-3 (No. 333-252664) earlier submitted with the U.S. Securities and Trade Commission (the “SEC”) and declared successful by the SEC on February 10, 2021. A preliminary prospectus dietary supplement has been submitted and accompanying prospectus describing the phrases of the proposed supplying will be submitted with the SEC and will be out there on the SEC’s website positioned at Copies of the securities acquire settlement and the convertible promissory observe relating to this financing can be attained at the SEC’s web-site at Ahead of investing in this offering, interested events should read in their entirety the prospectus supplement and the accompanying prospectus and the other paperwork that the Company has submitted with the SEC that are integrated by reference in these kinds of prospectus health supplement and the accompanying prospectus, which offer extra facts about the Enterprise and this sort of providing.

This push launch shall not constitute an offer you to offer or the solicitation of an offer to get nor shall there be any sale of these securities in any state or jurisdiction in which these kinds of provide, solicitation or sale would be illegal prior to registration or qualification less than the securities legal guidelines of any this kind of point out or jurisdiction.

About China SXT Prescribed drugs, Inc.

Launched in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an modern pharmaceutical company focusing on the investigation, growth, manufacture, advertising and marketing and revenue of traditional Chinese medication parts, which is a type of Traditional Chinese Drugs that has been processed to be ready for use. For extra information and facts, make sure you go to

Risk-free Harbor Statement

This press release contains forward-seeking statements as defined by the Personal Securities Litigation Reform Act of 1995. Forward-looking statements incorporate statements about programs, aims, plans, approaches, future situations or efficiency, and underlying assumptions and other statements that are other than statements of historical specifics. When the Enterprise uses phrases these types of as “may, “will, “intend,” “should,” “believe that,” “assume,” “foresee,” “task,” “estimate” or equivalent expressions that do not relate exclusively to historic matters, it is making ahead-hunting statements. Precisely, the Firm’s statements about the closing of the proposed personal placement are forward-wanting statements. Forward-on the lookout statements are not ensures of foreseeable future overall performance and contain pitfalls and uncertainties that may well lead to the true effects to vary materially from the Firm’s anticipations discussed in the forward-on the lookout statements. These statements are subject matter to uncertainties and pitfalls such as, but not restricted to, the next: the Firm’s aims and procedures the Company’s potential business enterprise advancement product or service and assistance need and acceptance changes in technology the progress of the pharmaceutical market, particularly the Traditional Chinese Drugs Items (“TCMPs”) market, in China status and brand name the affect of competitiveness and pricing government polices fluctuations in common economic and company problems in China and the intercontinental markets the Organization serves and assumptions underlying or associated to any of the foregoing and other pitfalls contained in reports filed by the Business with the Securities and Trade Fee. For these reasons, between other folks, investors are cautioned not to position undue reliance on any ahead-on the lookout statements in this push launch. Further elements are talked about in the Firm’s filings with the U.S. Securities and Exchange Commission, which are out there for overview at The Firm undertakes no obligation to publicly revise these ahead – looking statements to replicate occasions or situations that crop up after the day hereof.

Make contact with:
Title: Feng Zhou
Email: [email protected]